CMV pp65 (415-429) (HLA-B7) TPRVTGGGAM-acid

Description

CMV pp65 (415-429) (HLA-B7) is a CEF control peptide that is derived from the Cytomegalovirus (CMV).

See full description

Catalogue number crb1001454
Sequence (one letter code) TPRVTGGGAM-acid
Sequence (three letter code) H-Thr-Pro-Arg-Val-Thr-Gly-Gly-Gly-Ala-Met-OH
Purity >95%
Storage -20°C
Molecular Weight 945.5
References

La Rosa amd Diamond (2012). The immune response to human CMV. Future Virol. PMID: 23308079

Zhang et al (2012). How much of virus-specific CD8 T cell reactivity is detected with a peptide pool when compared to individual peptides? Viruses. PMID: 23202497

Liechti and Roederer (2019). OMIP-060: 30-Parameter Flow Cytometry Panel to Assess T Cell Effector Functions and Regulatory T Cells. Cytometry A. PMID: 31334913

CMV pp65 (415-429) (HLA-B7) is a CEF control peptide that is derived from the Cytomegalovirus (CMV). CMV is capable of infecting a wide range of human cell types, where the body’s primary immune response to CMV is innate, and relies on inflammatory cytokines and costimulatory molecules in order to control the spread of the virus. CMV pp65 (415-429) (HLA-B7) is defined as a CEF control peptide due to its antigenic properties. Clinically, these peptides are suitable epitopes for CD8+ T cells and can be used to stimulate the release of IFNg. HLA-B7 refers to the cell HLA type that this peptide acts on. 

CMV pp65 (415-429) (HLA-B7)

Cat No. Pack Size Price Qty

crb1001454h

0.5mg

$112.50

crb1001454j

1mg

$150.00